Search
Cue Biopharma Inc
CUEAdd to Watchlist
37.840USD
+3.670+10.74%
Close 09-17 16:00（ET）
196.78MMarket Cap
LossP/E TTM
More Details of Cue Biopharma Inc Company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Cue Biopharma Inc Profile
Ticker SymbolCUE
Company nameCue Biopharma Inc
IPO dateJan 02, 2018
CEOAzam (Usman)
Number of employees41
Security typeOrdinary Share
Fiscal year-endJan 02
Address40 Guest Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02135
Phone16179492680
Websitehttps://www.cuebiopharma.com/
Ticker SymbolCUE
IPO dateJan 02, 2018
CEOAzam (Usman)
Company Executives of Cue Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.67K
-72.08%
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.67K
-72.08%
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.67K
-72.08%
Dr. Pasha Sarraf, M.D., Ph.D.
Dr. Pasha Sarraf, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.20K
+63.02%
Dr. Pasha Sarraf, M.D., Ph.D.
Dr. Pasha Sarraf, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.20K
+63.02%
Dr. Pasha Sarraf, M.D., Ph.D.
Dr. Pasha Sarraf, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.20K
+63.02%
Dr. Pamela Garzone, Ph.D.
Dr. Pamela Garzone, Ph.D.
Independent Director
Independent Director
18.90K
--
Dr. Pamela Garzone, Ph.D.
Dr. Pamela Garzone, Ph.D.
Independent Director
Independent Director
18.90K
--
Dr. Pamela Garzone, Ph.D.
Dr. Pamela Garzone, Ph.D.
Independent Director
Independent Director
18.90K
--
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
933.00
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.67K
-72.08%
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.67K
-72.08%
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.67K
-72.08%
Dr. Pasha Sarraf, M.D., Ph.D.
Dr. Pasha Sarraf, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.20K
+63.02%
Dr. Pasha Sarraf, M.D., Ph.D.
Dr. Pasha Sarraf, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.20K
+63.02%
Dr. Pasha Sarraf, M.D., Ph.D.
Dr. Pasha Sarraf, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.20K
+63.02%
FAQs
Who are the top five shareholders of Cue Biopharma Inc?
The top five shareholders of Cue Biopharma Inc are: Dr. Shao-Lee Lin, M.D., Ph.D.
How many institutions hold shares of Cue Biopharma Inc (CUE)?
As of 2026Q1, 162 institutions hold shares of Cue Biopharma Inc, with a combined market value of approximately 21.86M, accounting for 319.68% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -851939.00.